Prelude Therapeutics Incorporated
PRLD
$1.00
$0.117313.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 33.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 33.33% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | 33.33% | |||
| SG&A Expenses | -6.78% | -21.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.52% | 1.22% | |||
| Operating Income | -2.29% | 1.59% | |||
| Income Before Tax | -11.67% | 10.97% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.67% | 10.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.67% | 10.97% | |||
| EBIT | -2.29% | 1.59% | |||
| EBITDA | -2.49% | 1.85% | |||
| EPS Basic | -11.49% | 10.98% | |||
| Normalized Basic EPS | -11.49% | 10.98% | |||
| EPS Diluted | -11.49% | 11.93% | |||
| Normalized Diluted EPS | -11.49% | 10.98% | |||
| Average Basic Shares Outstanding | 0.16% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||